VEGFR

VEGF is one of the key regulators of angiogenesis, vasculogenesis, and developmental hematopoiesis. It is a mitogen and survival factor for vascular endothelial cells while also promoting vascular endothelial cell and monocyte motility[1]. Binding of growth factors to the ectodomain of their transmembrane receptors leads to receptor dimerization, protein kinase activation, trans-autophosphorylation, and initiation of signaling pathways. The VEGF family of receptors (RTK class IV, VEGF receptor family) consists of three protein–tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3) and two non-protein kinase co-receptors (neuropilin-1 and 2)[2]. Targeting VEGF receptors proved to be a successful therapeutic approach for disorders with non-physiologic angiogenesis including age-related macular degeneration of the eye, diabetic retinopathy, rheumatoid arthritis, tumor growth and metastasis1.


[1] Vascular endothelial growth factor (VEGF) signaling during tumor progression. A comprehensive review of the discovery of the VEGF family of ligands and receptors. R. Roskoski Jr. Crit. Rev. Oncol. Hematol. 2007, 62, 179–213.
[2] VEGF receptor protein–tyrosine kinases: Structure and regulation. Mini Review. R. Roskoski Jr. Biochem. Biophys. Res. Com. 2008, 375, 287–291.

Items 31 to 33 of 33 total

per page
Page:
  1. 1
  2. 2
Axon ID Name Description From price
1411 Vandetanib VEGFR and EGFR tyrosine kinase inhibitor €50.00
1637 Vatalanib VEGFR tyrosine kinase inhibitor €75.00
1978 ZM 323881 hydrochloride Inhibitor of VEGFR2 €105.00

Items 31 to 33 of 33 total

per page
Page:
  1. 1
  2. 2
Please wait...